Rapid Study Migration for Oncotherapeutics
Oncotherapeutics, an oncology-focused CRO, was faced with extensive timelines and high costs to create complex studies, which was incredibly burdensome on their resources. TrialKit allowed them to migrate and launch their oncology studies in just a few days, and the plug-and-play nature of the platform drastically shortened the learning curve for the Oncotherapeutics team.
- Name Oncotherapeutics
- Type CRO
- Therapeutic Area Oncology
- # of Employees 10-50
Oncotherapeutics is a full service contract research organization (CRO) with a unique focus in oncology, offering a comprehensive service portfolio that supports preclinical studies and clinical trials from I to IV. Providing high quality deliverables to clients from small start-up biotech (16-50 employees), to large biotechnology and pharmaceutical companies (10k+ employees). Their full suite of services includes expert dedicated project teams, medical writing, data management, regulatory submissions, analysis and reporting.
As a provider of contract research services for various sized organizations with numerous sites, Oncotherapeutics found the labor intensive process and extensive timeline to create complex oncology studies, as well as the cost associated with each study, was taxing on both their administrative and economic resources. In addition, the training, support and oversight/monitoring required for each site was extensive.
Working in partnership with Crucial Data Solutions’ product managers, engineers and support & training teams, Oncotherapeutics was able to migrate an entire study from their prior EDC provider to TrialKit in a few short days and went on to create two new studies in a fraction of the time it had taken previously (3 days vs. 1 month).
The “plug-and-play” implementation of TrialKit, along with the unique ability to edit a live study, create and reuse templates, integrate conditional actions for more effective remote site monitoring, as well as query management, reporting, CRF submission and deviation from protocol alerts made for a seamless deployment and positive transition. Aside from the usability and proprietary features of TrialKit, the cost to engage, create and run studies is substantially less than the incumbent EDC.